Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
-

-

 
WKN: A2PZZR / Name: Bellerophon Therapeutics Inc. / Stock / Micro Cap /

Bellerophon Therapeutics Inc. Stock

Our community identified positive and negative aspects for Bellerophon Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Bellerophon Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Bellerophon Therapeutics Inc. in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Assessing the financials of Bellerophon Therapeutics Inc. provides a mixed picture, indicative of both the challenges it faces and the potential pathways forward. With a market capitalization just above $4.77 million, this biotechnology company appears to be navigating through turbulent waters, reflected in its financial ratios and statements. Investors may find themselves grappling with significant losses reported over the past few years, as well as a dearth of revenue generation, which is common within the biotech sector as firms often invest heavily in research and development prior to commercial success.

Potential for Growth: The company has a strong focus on research and development (R&D), with expenditures reaching over $16 million in the latest fiscal year. This investment may lead to future breakthroughs in treatment options, which could enhance revenue and recovery in the long run.

Book Value: With a book value of $0.46 per share, Bellerophon possesses some asset backing for its shares, providing a cushion for investors during volatile market conditions. This slight asset privilege implies some level of stability, despite the company's operational struggles.